Paper Details

  1. Home
  2. Paper Details

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting.

Author: DasPratik, GuptaSoumava, SanyalDebmalya

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

New-onset diabetes after transplantation (NODAT) is a common complication after kidney transplantation. The study evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients. Linagliptin monotherapy was found to be effective for glycemic control in NODAT, even in patients on glucocorticoids and standard-dose tacrolimus. There were no significant changes in tacrolimus drug levels or estimated glomerular filtration rate (eGFR), and minimal side effects, including weight gain and hypoglycemia. The results suggest linagliptin may be a safe and effective treatment option for NODAT, but further well-designed studies are needed.
Paper Details　
Original Abstract of the Article :
New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is eff...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830305/

データ提供：米国国立医学図書館（NLM）

Linagliptin for New-Onset Diabetes After Transplantation

The world of transplantation is a delicate balance between hope and risk. This study investigates the safety and efficacy of linagliptin, a diabetes medication, in treating new-onset diabetes after transplantation (NODAT). The researchers found that linagliptin was effective in controlling blood sugar levels in NODAT patients without significantly impacting kidney function or other medications.

Managing Diabetes After Transplantation

This study provides valuable information for clinicians managing diabetes in transplant recipients, offering a promising therapeutic option for NODAT.

Improving Outcomes for Transplant Recipients

This research highlights the potential for linagliptin to improve outcomes for transplant recipients with diabetes, potentially reducing complications and enhancing long-term health.

Dr. Camel's Conclusion

This study offers hope for transplant recipients struggling with NODAT, suggesting that linagliptin can effectively manage blood sugar levels while minimizing potential risks.

Date :
  1. Date Completed 2013-11-19
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24251159

DOI: Digital Object Identifier

PMC3830305

Related Literature

Article Analysis
・Side Effects of linagliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.